[Systemic inflammatory process as an etiological factor in increase of atherogenic potential of plasma].
The aim of the study was to investigate the role of systemic inflammation in the development of the atherogenic plasma abilities and to prevent the systemic inflammatory process by using fenofibrate (F.). An experimental model of inflammation was produced in 2 groups of rabbits, one of them received F. The activity of the systemic inflammation, oxidative stress, disturbances of lipoprotein metabolism, and the character and mechanisms of F. action were determined during 8 weeks of investigation. Under the primary character of the inflammation, induced in rabbits by intravenous injection of pirogenal, it was determined the distinct interdependence between activity of the systemic inflammatory process, monocytes activation, oxidative stress intensity, antioxidative plasma potential, the appearance of the lipoprotein atherogenic forms, hypercholesterolemia and hypertriglyceridemia. This dependence was confirmed in rabbits, treated with F. These data show that treatment with F. prevents hypercholesterolemia and hypertriglyceridemia development and suppresses the activity of inflammatory process.
Ruban
N V
NV
M.D. Straghesko Institute of Cardiology, Ukrainian Academy of Medical Sciences, Kiev.
D000818:Animals; D001161:Arteriosclerosis / Q000097:blood / Q000209:etiology* / Q000517:prevention & control; D004195:Disease Models, Animal; D011345:Fenofibrate / Q000627:therapeutic use*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008054:Lipid Peroxides / Q000097:blood; D008070:Lipopolysaccharides / Q000008:administration & dosage; D008074:Lipoproteins / Q000097:blood*; D018384:Oxidative Stress / Q000187:drug effects; D011817:Rabbits; D018746:Systemic Inflammatory Response Syndrome / Q000097:blood* / Q000150:complications
D000960:Hypolipidemic Agents; D008054:Lipid Peroxides; D008070:Lipopolysaccharides; D008074:Lipoproteins; C009136:pyrogenal; D011345:Fenofibrate